CN1617742B - 使用肿瘤-衍生的树突细胞抑制因子拮抗剂和Toll类受体激动剂的组合治疗癌症的方法 - Google Patents

使用肿瘤-衍生的树突细胞抑制因子拮抗剂和Toll类受体激动剂的组合治疗癌症的方法 Download PDF

Info

Publication number
CN1617742B
CN1617742B CN028275985A CN02827598A CN1617742B CN 1617742 B CN1617742 B CN 1617742B CN 028275985 A CN028275985 A CN 028275985A CN 02827598 A CN02827598 A CN 02827598A CN 1617742 B CN1617742 B CN 1617742B
Authority
CN
China
Prior art keywords
tumor
pharmaceutical composition
tlr
mage
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN028275985A
Other languages
English (en)
Chinese (zh)
Other versions
CN1617742A (zh
Inventor
A·P·维卡里
C·考克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1617742A publication Critical patent/CN1617742A/zh
Application granted granted Critical
Publication of CN1617742B publication Critical patent/CN1617742B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN028275985A 2001-11-27 2002-11-26 使用肿瘤-衍生的树突细胞抑制因子拮抗剂和Toll类受体激动剂的组合治疗癌症的方法 Expired - Fee Related CN1617742B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33343401P 2001-11-27 2001-11-27
US60/333,434 2001-11-27
PCT/US2002/038098 WO2003045431A2 (en) 2001-11-27 2002-11-26 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist

Publications (2)

Publication Number Publication Date
CN1617742A CN1617742A (zh) 2005-05-18
CN1617742B true CN1617742B (zh) 2010-10-27

Family

ID=23302758

Family Applications (1)

Application Number Title Priority Date Filing Date
CN028275985A Expired - Fee Related CN1617742B (zh) 2001-11-27 2002-11-26 使用肿瘤-衍生的树突细胞抑制因子拮抗剂和Toll类受体激动剂的组合治疗癌症的方法

Country Status (14)

Country Link
US (2) US20030138413A1 (enExample)
EP (1) EP1450858A2 (enExample)
JP (3) JP2006502080A (enExample)
CN (1) CN1617742B (enExample)
AU (1) AU2002359516B2 (enExample)
BR (1) BR0214457A (enExample)
CA (1) CA2468320A1 (enExample)
HU (1) HUP0500999A2 (enExample)
MX (1) MXPA04004998A (enExample)
NO (1) NO20042697L (enExample)
NZ (1) NZ565420A (enExample)
TW (1) TW200303759A (enExample)
WO (1) WO2003045431A2 (enExample)
ZA (1) ZA200404113B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103768604A (zh) * 2012-10-24 2014-05-07 北京圣沃德生物科技有限公司 治疗性肿瘤疫苗

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US20040175355A1 (en) * 2001-04-18 2004-09-09 The Regents Of The University Of California Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
US7387271B2 (en) * 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
US8795672B2 (en) * 2003-02-14 2014-08-05 University Of Southern California Compositions and methods for cancer immunotherapy
CN101675993A (zh) 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
WO2005014110A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
ES2689328T3 (es) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
JP2007526253A (ja) * 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性ウイルスｒｎａオリゴヌクレオチド
JP2008522951A (ja) * 2004-07-19 2008-07-03 ベイラー・カレツジ・オブ・メデイシン サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
WO2006014653A1 (en) * 2004-07-20 2006-02-09 Schering Corporation Induction of apoptosis in toll-like receptor expressing tumor cells
WO2007050095A2 (en) 2004-11-19 2007-05-03 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
JPWO2006077724A1 (ja) * 2004-12-28 2008-06-19 株式会社イミュノフロンティア がんワクチン製剤
EP1712241A1 (en) * 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
US20100143899A1 (en) * 2005-05-17 2010-06-10 University Of Vermont And State Agricultural College Methods and products for diagnosing cancer
CN101501055B (zh) * 2005-06-23 2016-05-11 贝勒医学院 负性免疫调节因子的调节和免疫疗法应用
EP1906989A4 (en) * 2005-07-11 2009-08-19 Cbio Ltd IMMUNOMODULATION INDUCED BY CHAPERONIN 10
NZ569086A (en) * 2005-12-01 2011-07-29 Trinity College Dublin Compositions comprising a Toll-like receptor (TLR) agonist and an immune modulator for treating Th1-mediated conditions, such as cancer and infectious diseases
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
SI2032592T1 (sl) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
DE102006035618A1 (de) * 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
EP2079305A4 (en) * 2006-12-12 2010-01-27 Idera Pharmaceuticals Inc SYNTHETIC AGONISTS OF TLR9
WO2008134020A1 (en) * 2007-04-26 2008-11-06 University Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
EP2222344A4 (en) * 2007-11-30 2012-11-07 Baylor College Medicine VACCINATE COMPOSITIONS WITH DENDRITIC CELLS AND THEIR USE
JP2012516352A (ja) * 2009-01-30 2012-07-19 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９の合成アゴニスト
JP5950824B2 (ja) 2009-12-07 2016-07-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗腫瘍抗体療法を増強するための方法
WO2011097384A2 (en) * 2010-02-04 2011-08-11 Board Of Regents, The University Of Texas System Tumor targeted delivery of immunomodulators by nanoplymers
US20130108661A1 (en) 2010-02-05 2013-05-02 Mount Sinai School Of Medicine Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
US9890202B2 (en) 2010-07-19 2018-02-13 Yeda Research And Development Co. Ltd. Peptides based on the transmembrane domain of a toll-like receptor (TLR) for treatment of TLR-mediated diseases
KR20130108295A (ko) * 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
EP2858722B8 (en) * 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
RU2678083C2 (ru) * 2012-06-27 2019-01-23 Кенитиро Хасуми Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10
CN104603156B (zh) 2012-09-05 2016-10-26 中外制药株式会社 引入有氨基酸和甾基的透明质酸衍生物
SG11201502796RA (en) 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
CN103013915B (zh) * 2013-01-09 2014-05-28 高岱清 一种高活性负载抗原的树突状细胞的制备方法
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
CN105377867B (zh) 2013-05-03 2019-11-12 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
PT3291821T (pt) * 2015-05-07 2026-03-18 Baylor College Medicine Imunoterapêutica com células dendríticas
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
MX2017015311A (es) * 2015-05-29 2018-06-19 Merck Sharp & Dohme Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.
KR102779525B1 (ko) * 2015-05-29 2025-03-12 다이나박스 테크놀로지 코퍼레이션 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여
US20200079860A1 (en) * 2015-08-06 2020-03-12 Memorial Sloan Kettering Cancer Center Methods and compositions for tumor therapy
TW201716084A (zh) * 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
CR20180229A (es) 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
WO2017192470A1 (en) * 2016-05-03 2017-11-09 Merck Sharp & Dohme Corp. Combination therapy of anti-il-10 antibody and compositions comprising lipid nanoparticles and tlr9 agonist cpg oligonucleotides
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018060513A1 (en) 2016-09-30 2018-04-05 Galderma Research & Development Methods and compositions for treating precancerous lesions or cancer comprising tlr/tlr or tlr/clr agonists
WO2018060514A1 (en) 2016-09-30 2018-04-05 Galderma Research & Development Methods and compositions combining at least one pattern recognition receptor (prr) agonist with an anti-il10 receptor antibody
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
IL268744B2 (en) * 2017-02-17 2024-08-01 Aivita Biomedical Inc Methods for increasing the immunogenicity of tumors and preparations for autologous immunotherapeutic products against cancer using tumor cells and adapted dendritic cells
EP3635410A4 (en) * 2017-06-04 2021-03-10 Rappaport Family Institute for Research in the Medical Sciences PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER TREATMENT USING IMMUNE CHECKPOINT INHIBITORS AND KITS
WO2019246111A1 (en) * 2018-06-19 2019-12-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand
CN113005090A (zh) * 2019-12-20 2021-06-22 上海细胞治疗集团有限公司 共表达趋化因子和共刺激分子的dc细胞及其应用
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
US20230210968A1 (en) * 2020-06-11 2023-07-06 Massachusetts Institute Of Technology Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016247A1 (en) * 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
WO2000062800A2 (en) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6194388B1 (en) * 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7397887A (en) * 1986-05-09 1987-12-01 Sloan-Kettering Institute For Cancer Research Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment
JPH08504766A (ja) * 1992-12-14 1996-05-21 スタート テクノロジー パートナーシップ ドーパミン作動性神経系の病態の診断および治療に関するドーパミン受容体ｍＲＮＡに対してアンチセンスのオリゴヌクレオチドの投与
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1261366A4 (en) * 2000-02-24 2003-06-18 Univ Leland Stanford Junior ADJUVANT TREATMENT BY IN VIVO ACTIVATION OF DENDRITIC CELLS
EP1283722A1 (en) * 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194388B1 (en) * 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1998016247A1 (en) * 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
WO2000062800A2 (en) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bauer S, et al..Human TLR9 confers responsiveness to bacterial DNAviaspecies-specific CpG motif recognition..PNAS98 16.2001,第9239页第一栏第10-29行、第二栏和图4.
Bauer S, et al..Human TLR9 confers responsiveness to bacterial DNAviaspecies-specific CpG motif recognition..PNAS98 16.2001,第9239页第一栏第10-29行、第二栏和图4. *
Castro AG, et al. 1529-1534.Anti-interleukin 10 receptor monoclonalantibodyisandadjuvant for T helper cell type 1 responsestosolubleantigenonly in the presence of lipopolysaccharide..J.Exp.Med.192 10.2000,第1531页第二栏第5行至第1533页第一栏第43行、图1和图2.
Castro AG, et al. 1529-1534.Anti-interleukin 10 receptor monoclonalantibodyisandadjuvant for T helper cell type 1 responsestosolubleantigenonly in the presence of lipopolysaccharide..J.Exp.Med.192 10.2000,第1531页第二栏第5行至第1533页第一栏第43行、图1和图2. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103768604A (zh) * 2012-10-24 2014-05-07 北京圣沃德生物科技有限公司 治疗性肿瘤疫苗

Also Published As

Publication number Publication date
NO20042697L (no) 2004-06-25
ZA200404113B (en) 2006-03-29
JP2006131638A (ja) 2006-05-25
AU2002359516B2 (en) 2006-02-02
NZ565420A (en) 2009-09-25
US20030138413A1 (en) 2003-07-24
US20090087440A1 (en) 2009-04-02
CA2468320A1 (en) 2003-06-05
BR0214457A (pt) 2006-11-21
CN1617742A (zh) 2005-05-18
TW200303759A (en) 2003-09-16
MXPA04004998A (es) 2005-04-08
HUP0500999A2 (en) 2007-11-28
WO2003045431A3 (en) 2004-01-22
EP1450858A2 (en) 2004-09-01
JP2006502080A (ja) 2006-01-19
WO2003045431A2 (en) 2003-06-05
AU2002359516A1 (en) 2003-06-10
JP2010053140A (ja) 2010-03-11

Similar Documents

Publication Publication Date Title
AU2002359516B2 (en) Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist
Chakraborty et al. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
Khong et al. Adjuvants for peptide-based cancer vaccines
US9950025B2 (en) Compositions and methods for treatment of neoplastic disease
AU2008265911B2 (en) Use of TLR agonists and/or type 1 interferons to alleviate toxicity of TNF-R agonist therapeutic regimens
JP2011026328A (ja) オリゴヌクレオチド組成物および免疫応答の調節のためのそれらの使用
KR20150022996A (ko) 암 면역요법을 위한 조성물 및 방법
Wang et al. Programmed polymersomes with spatio-temporal delivery of antigen and dual-adjuvants for efficient dendritic cells-based cancer immunotherapy
US20070292418A1 (en) Compositions and methods for immunotherapy
WO2018065625A2 (en) Immunogenic compounds for cancer therapy
AU2006200116B2 (en) Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist
Ursu et al. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma
KR20240109914A (ko) Trop2 면역원성 펩타이드
CN118541164A (zh) 核酸组合物及其用途
Zhang et al. An N-, C-terminally truncated basic fibroblast growth factor and LPD (liposome-polycation-DNA) complex elicits a protective immune response against murine colon carcinoma
Weeratna et al. Potential use of CpG ODN for cancer immunotherapy
Jyoti et al. played by nanoimmunoadjuvants
WO2026012340A1 (zh) CpG1018/1826/007/2006联合MNR的组合物用于治疗胰腺癌
KR20230101284A (ko) K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20230101286A (ko) K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20230101285A (ko) K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20240130054A (ko) K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
Meini Antitumor activity of locoregional combined CpG-ODN therapy in experimental carcinoma models

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101027

Termination date: 20101126